Jun 10, 2020
Debiopharm's Novel Microbiome Remodeling Program Licensed to Takeda for the Treatment of Gastrointestinal Disorders
May 26, 2020
Acquisition of Debiopharm's Investment Portfolio Company Kaiku Health Broadens Patient Access to Digital Oncology Intervention
Jan 09, 2020
Novadiscovery Raises Series A Financing to Scale its in silico Clinical Trial Platform - Debiopharm Leads the Round With EUR 5 Million
Jan 08, 2020
Knight Partners With Debiopharm for the Commercialization of Trelstar® in Canada
May 30, 2019
Caris Life Sciences Partners with Debiopharm International SA to Develop Companion Diagnostic for Detection of Rare FGFR Fusions Using Novel Molecular Intelligence (MI) Transcriptome(TM)
May 14, 2019
Debiopharm Awarded $2.1 Million From CARB-X in the Fight Against a Highly Resistant Nosocomial-Pneumonia Causing Superbug
Apr 30, 2019
GenePOC, a Subsidiary of Debiopharm Group, Reaches an Agreement With Meridian Bioscience for the Acquisition of Their Molecular Diagnostics Business
Apr 01, 2019
Debiopharm Releases Results of 3 Key Oncology Compound Programs at the 2019 American Association for Cancer Research (AACR) Conference in Atlanta, GA
Feb 14, 2019
Debiopharm International SA Initiates FUZE, a Clinical Trial Phase II Study Evaluating Debio 1347 in Advanced Solid Tumors Harboring an FGFR fusion
Jan 07, 2019
Debiopharm Group Regains the Commercial Rights to Trelstar® (Triptorelin pamoate) and Looks for New Partners in North America
Oct 11, 2018
Debiopharm International SA and the Paul Scherrer Institute Announce a Licensing Agreement for the Development of a Novel Targeted Radiotherapeutic Product in Oncology
May 08, 2018
FDA Grants Fast Track Designation to Debiopharm International's Debio 1347 for the Treatment of Patients With Unresectable or Metastatic Tumors With a Specific FGFR Gene Alteration
Apr 05, 2018
Kaiku Health Raises EUR4.4 Million Series A Financing to Accelerate Its Digital Therapeutics Pipeline Led by Debiopharm and Tesi
Feb 19, 2018
GenePOC Launches Its revogene(TM) Instrument and GBS LB Test in Canada
Feb 15, 2018
Debiopharm Continues the Fight Against Antibiotic Resistance With Investment in ABAC Therapeutics Inc.
Nov 28, 2017
GenePOC Launches its GenePOC(TM) CDiff Test in the United States
Nov 22, 2017
Debiopharm International SA Launches Clinical Trials Website: patients.debiopharm.com
Nov 14, 2017
EMA Grants Orphan Drug Designation to Debiopharm International SA's FGFR Inhibitor Debio 1347 in the Treatment of Biliary Tract Cancer
Nov 06, 2017
Debiopharm International SA Announces Dosing of First Patient in a Combination Trial of Debio 1143 and Avelumab in Patients with Solid Tumors including Non-Small Cell Lung Cancer (NSCLC)
Oct 12, 2017
GenePOC Launches its new GenePOC(TM) GBS DS Test